Clinical trials recruiting for Breast Neoplasms
105
Recruiting trials
48
US states with sites
53
Countries
10%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 17 |
| Texas | 15 |
| Florida | 13 |
| Massachusetts | 13 |
| New York | 13 |
| North Carolina | 12 |
| Virginia | 12 |
| Missouri | 11 |
| Michigan | 10 |
| New Jersey | 10 |
| Arizona | 9 |
| Colorado | 9 |
Top cities
Houston, Texas 13Boston, Massachusetts 12New York, New York 11Dallas, Texas 10Los Angeles, California 9Nashville, Tennessee 9St Louis, Missouri 8Detroit, Michigan 7New Brunswick, New Jersey 7Santa Monica, California 7
Self-screener
Recruiting trials
- 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
- A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China
- A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
- A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
- A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
- A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)
- A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
- AI-Based Phenome Data Analysis for Predicting the Onset of Major Diseases
- ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)
- Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer
- Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
- Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
- Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen
- Assessment of Oncological Safety, Quality of Life, and Environmental Impact of the Green Breast Surgery Protocol
- Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations
- Biennial CEM in Women With a Personal History of Breast Cancer
- Breast Cancer and Resilience in Couple
- Breast Cancer, Reasoning, and Activity Intervention
- Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer
- Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
- Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
- Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models
- DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast
- DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes
- DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
- Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
- Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression
- Dissemination of BREASTChoice AIM1-B
- Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients
- Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- Effect of Preoperative Exercise on the Prevention of Secondary Lymphedema in Breast Cancer Patients
- Effects of Online Yoga on the Quality of Life of Breast Cancer Patients
- Effects of a Telerehabilitation Intervention in the Management of Complications After Breast Cancer Surgery
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
- Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
- Establishment of a Tumor Bank for Blood Samples
- Establishment of a Tumor Bank for Tissue Samples
- Evaluation of Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients
- Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
- Feasibility of a Preoperative, Multimodal Lifestyle Intervention in Patients With Breastcancer
- Fluorocholine PET/MR in Breast Cancer
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- ICG Lymphoscintigraphy Changes Before and After Radiotherapy in Breast Cancer Patients
- Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients
- Impact of Nipple Reconstruction in Mastectomized Patients Using Cross-Linked Hyaluronic Acid Injection.
- Impact of Prehabilitation and Comprehensive Follow-up in Women With Breast Cancer
- Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients
- Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
- Longitudinal Body Composition Assessment in Breast Cancer Patients
- ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
- Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia
- Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
- Neoadjuvant Radiation in Locally Advanced Breast Cancer
- Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
- Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
- Omission of Axillary Surgery in Breast Cancer Patients
- OvS Breast: Ovarian Suppression in Breast Cancer Interventions
- PARTial BREast RECONstruction With Chest Wall Perforator Flap
- PREgnancy and FERtility Registry
- Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
- PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
- Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer
- Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
- Preoperative Radiation Therapy and Immediate Breast Reconstruction
- Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
- RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort
- Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
- Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
- Reliability and Validity of Ultrasound for the Assessment of Soft Tissue Properties After Breast Cancer Treatment
- Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B
- Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer
- Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases
- Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
- Slow Jogging for Breast Cancer Survivors
- Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
- Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Surgical Outcome of BCS Using ICG-F in Breast Cancer Patients After Preoperative Chemotherapy
- Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
Related conditions
Trials recruiting for Breast Neoplasms often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Lung cancer 2180Colorectal Neoplasms 61Colorectal cancer 1359Breast Diseases 8Lung Neoplasms 33Ovarian Neoplasms 18Hormone Receptor Positive Breast Cancer 24Breast Carcinoma 74Breast Cancer Female 61
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Breast Neoplasms trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.